Vitamin D normalizes brain waves
- Trial ID
- NCT07096336
- Official Title
- Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis
- Goal
- Vitamin D normalizes brain waves
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Bangladesh Medical University
- Study Type
- INTERVENTIONAL
- Enrollment
- 15 participants
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- vitamin D3 capsule
Plain-Language Summary
The goal is to see whether correcting low vitamin D can change abnormal brain wave patterns in men with Parkinson's, which could reflect altered neuronal excitability and brain function. Participants will take an oral vitamin D3 capsule to raise serum 25(OH)D; vitamin D3 acts on neurons and calcium signaling and may reduce neuronal hyperexcitability, and researchers will measure quantitative EEG while patients stay on their usual levodopa because vitamin D3 is not expected to change how levodopa works. The study seeks men aged 51 to 70 with Parkinson's up to Hoehn and Yahr stage 3, BMI 18.5 to 24.9, confirmed hypovitaminosis D (<30 ng/ml), who are on levodopa and not already taking vitamin D or other medications or having medical conditions that affect EEG or calcium metabolism, and active smokers are excluded.
Locations
- Bangladesh medical university, Dhaka, Shahbag, Bangladesh
Frequently Asked Questions
- What is this trial testing?
- This trial is studying vitamin D3 capsule. The goal is to see whether correcting low vitamin D can change abnormal brain wave patterns in men with Parkinson's, which could reflect altered neuronal excitability and brain function. Participants will take an oral vitamin D3 capsule to raise serum 25(OH)D; vitamin D3 acts on neurons and calcium signaling and may reduce neuronal hyperexcitability, and researchers will measure quantitative EEG while patients stay on their usual levodopa because vitamin D3 is not expected to change how levodopa works. The study seeks men aged 51 to 70 with Parkinson's up to Hoehn and Yahr stage 3, BMI 18.5 to 24.9, confirmed hypovitaminosis D (<30 ng/ml), who are on levodopa and not already taking vitamin D or other medications or having medical conditions that affect EEG or calcium metabolism, and active smokers are excluded.
- Who can participate?
- Participants must be between 51 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 months.